DK1799633T3 - Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger - Google Patents

Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger

Info

Publication number
DK1799633T3
DK1799633T3 DK05770026.2T DK05770026T DK1799633T3 DK 1799633 T3 DK1799633 T3 DK 1799633T3 DK 05770026 T DK05770026 T DK 05770026T DK 1799633 T3 DK1799633 T3 DK 1799633T3
Authority
DK
Denmark
Prior art keywords
methylpropyl
dimethylamino
ethyl
active ingredient
pharmaceutical compositions
Prior art date
Application number
DK05770026.2T
Other languages
English (en)
Inventor
Andreas Fischer
Helmut Buschmann
Michael Gruss
Dagmar Lischke
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1799633(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK1799633T3 publication Critical patent/DK1799633T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK05770026.2T 2004-06-28 2005-06-27 Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger DK1799633T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04015091A EP1612203B1 (en) 2004-06-28 2004-06-28 Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
PCT/EP2005/006884 WO2006000441A2 (en) 2004-06-28 2005-06-27 Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

Publications (1)

Publication Number Publication Date
DK1799633T3 true DK1799633T3 (da) 2011-03-28

Family

ID=34925507

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04015091T DK1612203T3 (da) 2004-06-28 2004-06-28 Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
DK05770026.2T DK1799633T3 (da) 2004-06-28 2005-06-27 Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK04015091T DK1612203T3 (da) 2004-06-28 2004-06-28 Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid

Country Status (27)

Country Link
US (16) US20070213405A1 (da)
EP (2) EP1612203B1 (da)
JP (1) JP4990764B2 (da)
KR (1) KR101096501B1 (da)
CN (1) CN1997621B (da)
AR (2) AR049949A1 (da)
AT (2) ATE368639T1 (da)
AU (1) AU2005256512B2 (da)
BR (2) BR122018014454B8 (da)
CA (1) CA2572147C (da)
CY (2) CY1106929T1 (da)
DE (2) DE602004007905T2 (da)
DK (2) DK1612203T3 (da)
EC (1) ECSP17046065A (da)
ES (2) ES2291780T3 (da)
HR (1) HRP20110050T8 (da)
IL (1) IL180373A (da)
MX (1) MXPA06014741A (da)
NO (3) NO338605B1 (da)
NZ (1) NZ551605A (da)
PE (1) PE20060372A1 (da)
PL (2) PL1612203T3 (da)
PT (2) PT1612203E (da)
RU (1) RU2423345C2 (da)
SI (2) SI1612203T1 (da)
WO (1) WO2006000441A2 (da)
ZA (1) ZA200700774B (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
SI1612203T1 (sl) * 2004-06-28 2007-12-31 Gruenenthal Chemie Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
WO2009071310A1 (de) 2007-12-07 2009-06-11 Grünenthal GmbH Kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
BRPI0906467C1 (pt) 2008-01-25 2021-05-25 Gruenenthal Gmbh forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
KR101690094B1 (ko) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
WO2011138037A2 (de) 2010-05-05 2011-11-10 Ratiopharm Gmbh Festes tapentadol in nicht-kristalliner form
WO2012010316A1 (en) 2010-07-23 2012-01-26 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
CA2808541C (en) 2010-09-02 2019-01-08 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
PT2680834T (pt) 2011-03-04 2018-01-25 Gruenenthal Gmbh Composição farmacêutica aquosa semissólida contendo tapentadol
SI2680832T1 (sl) 2011-03-04 2019-11-29 Gruenenthal Gmbh Vodna farmacevtska formulacija tapentadola za peroralno dovajanje
DK2680833T3 (da) * 2011-03-04 2016-05-23 Gruenenthal Gmbh Parenteral indgivelse af tapentadol
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CZ304576B6 (cs) * 2012-07-24 2014-07-16 Zentiva, K.S. Oxalát TAPENTADOLU a způsob jeho přípravy
CN102924303B (zh) * 2012-10-31 2013-11-20 合肥市新星医药化工有限公司 盐酸他喷他多晶型c及其制备方法和应用
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
US9599565B1 (en) * 2013-10-02 2017-03-21 Ondax, Inc. Identification and analysis of materials and molecular structures
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
CZ307492B6 (cs) 2014-02-04 2018-10-17 Zentiva, K.S. Pevná forma maleátu tapentadolu a způsob její přípravy
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
CN107847471A (zh) 2015-03-27 2018-03-27 格吕伦塔尔有限公司 他喷他多肠胃外给药的稳定制剂
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
DK3445742T3 (da) 2016-04-19 2020-02-24 Ratiopharm Gmbh Krystallin tapentadolphosphat
EP3515412A1 (en) 2016-09-23 2019-07-31 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
US11492342B2 (en) 2020-11-03 2022-11-08 Landos Biopharma, Inc. Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
BR9711151A (pt) * 1996-08-14 1999-08-17 Searle & Co Forma cristalina de 4-¬5-metil-3-fenilsoxazol-4-il¾benzenossulfonamida
EP1330427A1 (en) * 2000-10-31 2003-07-30 Ciba SC Holding AG Crystalline forms of venlafaxine hydrochloride
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
CN1275936C (zh) * 2001-09-13 2006-09-20 橘生药品工业株式会社 羟基去甲麻黄素衍生物的各种结晶体型
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
SI1612203T1 (sl) * 2004-06-28 2007-12-31 Gruenenthal Chemie Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida

Also Published As

Publication number Publication date
DE602005026031D1 (de) 2011-03-03
CY1106929T1 (el) 2012-09-26
US20230174458A1 (en) 2023-06-08
PE20060372A1 (es) 2006-05-08
EP1612203B1 (en) 2007-08-01
BR122018014454B1 (pt) 2019-09-03
US20200385334A1 (en) 2020-12-10
IL180373A (en) 2012-05-31
AU2005256512B2 (en) 2011-05-19
US20180230082A1 (en) 2018-08-16
NZ551605A (en) 2010-01-29
US20180029976A1 (en) 2018-02-01
ES2291780T3 (es) 2008-03-01
DE602004007905T2 (de) 2008-05-08
US20100160447A1 (en) 2010-06-24
KR101096501B1 (ko) 2011-12-20
EP1799633B1 (en) 2011-01-19
US20200102261A1 (en) 2020-04-02
MXPA06014741A (es) 2007-02-12
NO20160914A1 (no) 2007-01-24
US20190062263A1 (en) 2019-02-28
EP1612203A1 (en) 2006-01-04
PL1799633T3 (pl) 2011-06-30
BRPI0512792A (pt) 2008-04-08
RU2007103297A (ru) 2008-08-10
EP1799633A2 (en) 2007-06-27
RU2423345C2 (ru) 2011-07-10
US20160122287A1 (en) 2016-05-05
NO20171103A1 (no) 2007-01-24
ATE496021T1 (de) 2011-02-15
US20170166515A1 (en) 2017-06-15
SI1612203T1 (sl) 2007-12-31
HRP20110050T1 (hr) 2011-02-28
NO341239B1 (no) 2017-09-25
JP2008504326A (ja) 2008-02-14
PL1612203T3 (pl) 2007-12-31
DE602004007905D1 (de) 2007-09-13
WO2006000441A3 (en) 2006-05-04
US7994364B2 (en) 2011-08-09
AR116052A2 (es) 2021-03-25
JP4990764B2 (ja) 2012-08-01
NO343922B1 (no) 2019-07-08
CN1997621A (zh) 2007-07-11
CA2572147A1 (en) 2006-01-05
US20110294898A1 (en) 2011-12-01
US20120302643A1 (en) 2012-11-29
AR049949A1 (es) 2006-09-20
ES2359504T3 (es) 2011-05-24
AU2005256512A1 (en) 2006-01-05
CY1111530T1 (el) 2015-08-05
NO20070162L (no) 2007-01-24
US20210261492A1 (en) 2021-08-26
US20070213405A1 (en) 2007-09-13
WO2006000441A2 (en) 2006-01-05
KR20070039929A (ko) 2007-04-13
HRP20110050T8 (en) 2011-03-31
SI1799633T1 (sl) 2011-05-31
BR122018014454B8 (pt) 2021-07-27
US20140011886A1 (en) 2014-01-09
PT1612203E (pt) 2007-08-20
DK1612203T3 (da) 2007-12-03
US20140296346A1 (en) 2014-10-02
IL180373A0 (en) 2007-06-03
US20090186947A1 (en) 2009-07-23
NO338605B1 (no) 2016-09-12
ZA200700774B (en) 2008-09-25
ECSP17046065A (es) 2018-11-30
ATE368639T1 (de) 2007-08-15
CN1997621B (zh) 2011-06-15
PT1799633E (pt) 2011-03-07
CA2572147C (en) 2012-10-30

Similar Documents

Publication Publication Date Title
DK1799633T3 (da) Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
DK1786403T3 (da) Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
DK1792927T3 (da) Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens
DK2046724T3 (da) Fremgangsmåde til fremstilling af (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
DK1732917T3 (da) Udvalgte CGRP-antagonister, fremgangsmåde til fremstilling deraf, samt anvendelse deraf som lægemiddel
DK1789405T3 (da) Nye enantiomerrene betaagonister, fremgangsmåder til deres fremstilling og deres anvendelse som lægemiddel
DK2361609T3 (da) Formulering af småmolekylære lægemidler med forsinket frigivelse
DK1786785T3 (da) Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
DK1776010T3 (da) Fremgangsmåde til fremstilling af vandige aktivstofsammensætninger af aktivstoffer, som er tungt oplöselige i vand
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
CY1118976T1 (el) Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης
DK1932522T3 (da) Terapeutisk middel mod leversygdom indeholdende 2-amino-1,3-propandiolderivat som aktiv bestanddel
FI20041129A0 (fi) Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
MA28603B1 (fr) Composition pharmaceutique antimycobacterienne
NO20074676L (no) Krystallinske former av (1 RS, 3RS, 6RS)-6-dimetylaminometyl-1-(3-metoksy-fenyl)cykloheksan-1,3-diol hydroklorid
NO20050391D0 (no) Nye fluorinerte benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
EA200901387A1 (ru) Фармацевтическая композиция, включающая дезлоратадин
EA200970167A1 (ru) Фармацевтическая композиция, содержащая комбинацию саредутанта и селективного ингибитора обратного захвата серотонина или ингибитора обратного захвата серотонина/норэпинефрина